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Abstract
Background: In vitro evidence indicates that tetrandrine (TT) can potentiate the action of chloroquine 40-fold
against choloquine-resistant Plasmodium falciparum. The key question emanating from that study is “would
tetrandine and chloroquine be highly effective in a live Aotus monkey model with chloroquine-resistant parasites”.
This study was designed to closely mimic the pharmacological/anti-malarial activity in man.
Methods: The Vietnam Smith/RE strain of P. falciparum, which is chloroquine-resistant was used in this study.
Previous experimental procedures were followed. Panamanian owl monkeys (Aotus) were inoculated with 5×106
erythrocytes parasitized with the CQ-resistant strain of P. falciparum. Oral drug treatment was with CQ (20 mg/kg)
and/or tetrandrine at 15 mg/Kg, 30 mg/Kg or 60 mg/Kg or 25 mg/Kg depending on experimental conditions.
Results and Discussion: Parasitaemia was cleared rapidly with CQ and TT while CQ treatment alone was
ineffective. Recrudescence of malaria occurred after seven days post-infection. However, four animals were treated
orally with TT and CQ parasites were cleared. It is likely that monkeys were cured via a combination of both drug
and host immune responses. A single Aotus monkey infected with P. falciparum and untreated with drugs, died.
No side effects were observed with these drug treatments.
Conclusions: This combination of chloroquine and tetrandrine forms the basis of a new attack on chloroquineresistant malaria - one based upon inhibition of the basis of chloroquine resistance, the multiple drug resistance
pump. Previous studies demonstrated that the parasite MDR pump was found on parasite membranes using 3H
azidopine photoaffinity labelling.
Since MDR-based choloroquine resistance is induced by chloroquine, the basis of the action of tetrandrine is the
following: 1) tetrandrine inhibits the MDR pump by stimulating MDR ATPase which limits the energy of the pump
by depletion of parasite ATP, 2) tetrandrine blocks the genetic factor which controls the induction of the pump.
Therefore, it appears that the parasite cannot outsmart these mechanisms and produce a new mode of resistance.
Only time will tell if this is correct.
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Background
Chloroquine has been, and probably still is, the most
used anti-malarial drug throughout the world. The
emergence and spread of chloroquine (CQ)-resistant falciparum malaria has evoked a search for new drugs effective against this drug-resistant parasite. However, the
malarial parasite rapidly develops resistance to new antimalarial drugs; for example, mefloquine and, more recently, artemisinin [1]. In 1987, Martin and co-workers
explored a different method to attack the drug resistant
parasite with the use of racemic verapamil combined
with CQ. This combination reversed the resistance of
the parasite in vitro [2], similar to its action in drug resistant cancer. However, at the extensive doses which reversed chloroquine resistance, verapamil exhibits cardiac
toxicity in humans, which makes it impractical clinically.
Since then, much work has been focused on reversal
of the resistance to CQ by using various compounds,
such as calcium channel blockers [3] and their isomers
[4-6], antidepressive drugs [7-9], antihistaminics [10-17].
However, most of the above combinations, which reversed the resistance in vitro, have not been successful
in vivo either using the Aotus monkey [18] or doing clinical trials [19]. It has been previously reported that
tetrandrine, a bisbenzyl isoquinoline, possesses a unique
anti-malarial activity, especially selective against CQresistant Plasmodium falciparum [20], and that a combination of tetrandrine with CQ displayed a strong
synergism against both CQ-sensitive and CQ-resistant
P. falciparum in vitro [21]. The data obtained in vitro indicated that this TT/CQ combination was able to increase anti-malarial potency of chloroquine, such that a
standard dose of CQ (1.5 g/patient) presumably might
actually cure chloroquine-resistant falciparum malaria in
humans.
Initially, an in vitro system was used to find active
anti-malarial drugs or drug combinations. The situation
in vivo is much more complex since biological activity is
greatly affected by absorption (if given orally), distribution, metabolism, and excretion of the drug. Therefore,
the data obtained in vitro cannot be directly extrapolated
in vivo. Results with the tetrandrine-CQ combination
in vitro must be tested in an in vivo system.
This study uses Aotus monkeys infected with a CQresistant strain of P. falciparum to confirm the effectiveness of the combination against CQ-resistant parasites
in vivo. The aim of this study was to provide a pharmacodynamic basis for a possible human clinical trial with
this combination.
Methods
The Vietnam Smith/RE strain of P. falciparum, which
is CQ-resistant, was used in this study. Experimental
procedures described previously were followed [18,22].
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Briefly, Panamanian owl monkeys (Aotus lemurinus lemurinus)(Figure 1) were inoculated intravenously with
5 × 106 erythrocytes parasitized with this CQ-resistant
strain of P. falciparum. Five days after the inoculation,
parasitaemia in the monkeys was about 5 × 103/mm3,
when the treatment with the combination initiated. In
conducting the research described in this report, the investigators adhered to “Guide for the Care and Use of
Laboratory Animals, prepared by the Committee on
Care and Use of Laboratory Animals of the Institute of
Laboratory Animals Resources of the Institute of Animal Resources, National Council ( DHEW publication
No. (NIH) 78-23 Revised 1978).
A water-solution of both CQ diphosphate and tetrandrine dihydrochloride was prepared respectively at appropriate concentrations. Just before treatment, the two
drug solutions were mixed and given orally by gastric intubation in a volume of 7.0 ml, followed by 7.0 ml water
for rinse.
Treatment regimens in the experiments were divided
into two categories. One-week therapy: After infection
with the CQ-resistant parasite, the monkey was treated
consecutively for seven days with CQ (20 mg/kg) combination with different doses of tetrandrine ranging from
15 to 60 mg/kg. If recrudescence occurred, the dose of

Figure 1 The picture below is an Aotus monkey similar to the
animals used in this study. The original source was wikimedia
commons and is used with permission.
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tetrandrine in the combination was increased two times
the initial dose for another one-week therapy. Two-week
therapy: Instead of an increased dose of tetrandrine, the
duration of treatment was changed from one week to
two weeks.
A control, infected monkey was not given drug. In
addition, five infected monkeys were administered CQ
orally alone for seven consecutive days.
Blood smears were made daily during the experiment
to monitor parasitaemia. After clearance of parasitaemia,
a three-month follow-up was done to ascertain cure of
infections.

Results
Two experiments with Aotus monkeys treated with the
combination of tetrandrine and CQ were conducted. In
the first experiment, 15 mg/kg tetrandrine and 20 mg/kg
CQ were given orally to three monkeys infected with
CQ-resistant P. falciparum for seven consecutive days.
In the second experiment, two monkeys were treated
with the combination of 30 or 60 mg/kg tetrandrine and
20 mg/kg CQ for seven consecutive days. The results are
summarized in Table 1.
The CQ-resistant P. falciparum parasites were cleared
in a mean of 9.2 days, ranging from 7 to 16 days after
initial treatment with the drug combination (Table 1).
Infections recrudesced in all the treated monkeys within
one month after clearance of the parasite. In the first

experiment, monkeys No. 025 and 016 were treated for
another week with a higher dose of tetrandrine (30 mg/kg)
combined with the CQ (20 mg/kg) after recrudescence occurred. One of the two monkeys was cured following the
second treatment.
Following the recrudescence in the second experiment,
re-treatment of monkeys No. 705 and 706 for one week
with a higher dose of tetrandrine (60 mg/kg) did not
cure the infections (recrudescence occurred again), although parasitaemia was rapidly cleared. A two-week
therapy with a lower dose of tetrandrine (25 mg/kg)
combined with the same dose of CQ (20 mg/kg) was
used to treat monkeys No. 705, 706 and 725. No recrudescence occurred during the post-treatment examination period.
The infected monkey without any drug treatment died
within two weeks. In monkeys treated with CQ alone,
the parasite response to CQ alone was none or a slight
suppression. The parasitaemia in three of five monkeys
treated with CQ alone increased continuously during the
treatment with CQ, while the parasitaemia in the
remaining two monkeys was suppressed slightly.

Discussion
The results obtained in Aotus monkeys infected with
CQ-resistant P. falciparum showed that the tetrandrine
combination with CQ can rapidly clear parasitaemia,
while the parasite is not affected or only slightly affected

Table 1 Effect of the combination of tetrandrine and chloroquine against infected chloroquine-resistant Plasmodium
falciparum malaria in Aotus monkeys
Expt. no.

Monkey no.

Dosea (Mg/kg)

Parasites
cleared

1

025

15(tt)

+

20(cq)
055

15(tt)

16

15(tt)

705

30(tt)
60(tt)

8

13
9

+
-

520

20(cq)

-

432

20(cq)

-

349

20(cq)

-

544

20(cq)

-

631

20(cq)

-

(++)

20 (cq)

a tt and cq represent tetrandrine and chloroquine respectively.
b This monkey as a non-treated control died within 2 weeks after inoculation with the parasite.
c Monkeys were treated with CQ alone.
d Monkeys were cured after two week combinational cq and tt treatment=(++).

14

(++)

20(cq)
(++)

20 (cq)
(++)

20 (cq)
120 (tt)

7

-

30 (tt) d

60 (tt) d
7

698b

Cured

30 (tt) d

+

20(cq)
CQc

33

+

20(cq)
706

23

Re-treating-post
recrudescence
(mg/kg)

30(tt) d
8

20(cq)
2

Days from final
dose to recrudescence

+

20(cq)
016

Days from initial
dose to parasite
clearance

d

20 (cq)

(++)
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by CQ alone (see Table 1). This is similar to a report that
the Vietnam Smith/RE strain of P. falciparum is very resistant to CQ, because the drug exerted limited effects
on parasitaemia in Aotus monkeys that received 20 mg/
kg/day of CQ for several days [18]. Tetrandrine in combination with CQ may either increase total anti-malarial
activity or inhibit the resistance of the parasite to CQ or
both, so that a dose of CQ (20 mg/kg) in combination
with tetrandrine exerts a remarkably potent anti-malarial
effect against the CQ-resistant P. falciparum strain. Later work in cancer indicates that tetrandrine inhibits the
transcription factor nuclear factor kappa b. This transcription factor is now known to control the stimulation
of multiple drug resistance (MDR) mechanism. This
cancer MDR mechanism is quite similar to the MDR
pumping system that causes the exit pumping of chloroquine in drug resistant malarial parasites. Therefore, it
should not be surprising that tetrandrine could inhibit
either or both the production of the pump or the pumping action of the chloroquine- resistance pump (MDR).
In fact, these events both happen in MDR drug resistant
cancer cells. The tetrandrine/CQ combination creates a
major synergism that was observed in the in vitro studies with chloroquine resistance in human falciparum
malaria [21].
Recrudescence occurred after the one-week treatment
with the drug combination. Following recrudescence in
the first experiment, re-treatment of the monkeys with a
larger dose of tetrandrine combined with chloroquine
did clear the resistant malaria and cured infection in one
monkey without the second treatment. In the second experiment, re-treatment with a higher dose of tetrandrine
in the combination did not eliminate all the parasites in
the monkeys, although the dose of tetrandrine in the
combination was increased up to 120 mg/kg. Apparently, the increased dose of tetrandrine does not overcome the basis of recrudescence. Therefore, the length
of therapeutic regimen was changed from one week to
two weeks. No recrudescence occurred after the twoweek treatment. It seemed that increasing the period of
drug exposure to the parasite might be an effective
method to overcome recrudescence. However, the likely
possibility that host defense was partly responsible for
the cure of these monkeys cannot be ruled out, because
the monkeys that were treated with the two-week therapy are the same animals that had already received-the
one-week treatment twice before; i.e., these monkeys
had gone through a process of malarial infection: 7 days
treatment - clearance of parasitaemia - recrudescence 7 days retreatment - clearance of parasitaemia - recrudescence. In addition, it has been previously recognized
there is some self-cure or spontaneous recovery that occurs naturally in these monkeys infected with P. falciparum. Maybe the cure of falciparum infection in these
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monkeys was elicited either by an effect of the two-week
treatment, or partially by a spontaneous recovery, or
more likely a combination of the drugs and this host
defense. Therefore, it cannot be stated with certainty
that the drugs were entirely responsible for the cure. Although the cause of recrudescence is not clear, the following possibilities were considered. Either the initial
duration of exposure of the parasite to the drug combination is too short to kill all the parasites, or the concentration of tetrandrine is not enough for a long enough
time at the site of action so that parasites that are hiding
can survive, or both.
Tetrandrine is a bisbenzyl isoquinoline alkaloid, isolated from Stephania tetrandra, which has been used in
traditional Chinese medicine either as an anti-rheumatic
or analgesic agent. Tetrandrine is an approved drug in
China, which has been used to treat hypertension and
silicosis for centuries since it exerts known pharmacological activities on the cardiovascular system and produces anti-inflammatory activity [23-26]. Tetrandrine
was found to exert little toxicity in clinical practice [23].
It can be given orally to humans at the dose of 200 mg
or 300 mg/day for three months when used for treatment of silicosis [23]. Hence, tetrandrine is a relatively
safe drug. Although no toxicological studies per se were
performed on these monkeys, using the tetrandrine/CQ
combination in this experiment; the monkeys appeared
to easily tolerate orally a high dose of 120 mg/kg of
tetrandrine in the combination with CQ at a dose of 20
mg/kg. One reason for other drug combinations failing
when used at high doses in in vivo experiments, including clinical trials, was linked to their inherent toxicity. It
seems that tetrandrine has relatively low toxicity. Therefore, it may be practical and helpful to conduct a clinical
trial on the combination of tetrandrine and CQ on a small
scale after further verifying the combinational safety of the
tetrandrine with CQ.

Conclusions
Based on data obtained in Aotus monkeys infected with
CQ-resistant parasites, it can be concluded that the
tetrandrine-CQ combination is effective against chloroquine-resistant falciparum malaria in Aotus monkeys.
This combination can clear the parasitaemia rapidly, although some recrudescence occurred after treatment. In
addition, a longer period of treatment; for example, a
two-week’s application, might solve the recrudescence
problem caused by the shorter treatment (one-week
therapy). Artemisinin and its derivatives also displayed
recrudescence in clinical trials as well as in animal experiments. By prolonging duration of the treatment with
artemisinin or its derivatives, the recrudescence problem
was essentially resolved. A further study of the effectiveness of a two-week treatment with the CQ/tetrandrine
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drug combination using a total of five Aotus monkeys to
confirm the curative effectiveness of the two-week therapy is warranted.
There was not sufficient funds to continue these studies. Although statistical analysis was not accomplished,
the cure of all five drug-treated animals after the 7–14
day combinational treatment leads one to an obvious
conclusion that the combination of chloroquine and
tetrandrine with an intact host immune system is an effective treatment of Aotus-infected falciparum malaria if
treated for the correct amount of time. Both tetrandrine
and chloroquine have been used in man as single entities
for years. By combining the drugs to treat chloroquine
resistant falciparum malaria in man would likely be an
effective combination in man without major toxicity
from either drug alone. Tetrandrine is metabolized in
man and animals with great difficulty because it is a
weak substrate for liver p-450 oxidation system. However, only a study in man with chloroquine-resistant,
falciparum malaria could reveal the necessary data to
confirm this research in Aotus monkeys. Since MDRbased choloroquine resistance is induced by chloroquine
[27], the basis of the action of tetrandrine is the following: 1) tetrandrine inhibits the MDR pump by stimulating MDR ATPase which limits the energy of the pump
by depletion of parasite ATP, 2) tetrandrine blocks the
genetic factor which controls the induction of the pump.
Therefore, it appears that the parasite cannot outsmart
these mechanisms and produce a new mode of resistance. Only time will tell if this is correct.
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